arrow
F

Federico Lussana

university of milan
H指数:28
被引数:3,947

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Favorable outcomes after early allogeneic stem cell transplantation in adult early T-cell precursor acute lymphoblastic leukemia treated with the pediatric-inspired GIMEMA LAL1913 program. A Campus ALL study

成人早期T细胞前体急性淋巴细胞白血病患者在接受儿科启发式GIMEMA LAL1913方案治疗后,早期同种异基因干细胞移植的积极结果。Campus ALL研究

2026-07-160
PRE
Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols
2026-07-080
OA
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series

体外细胞因子血吸附治疗B细胞恶性肿瘤T细胞免疫治疗继发性严重糖皮质激素难治性细胞因子释放综合征:一个病例系列

2026-06-220
OA
Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter

异基因造血干细胞移植在原始细胞危象期骨髓纤维化患者中的结局:分子特征和强化化疗至关重要

2026-05-300
OAAI
Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement

阿伐普利尼布靶向KIT D816V突变型急性髓系白血病,该病在异基因造血干细胞移植后复发,并伴有髓外及中枢神经系统浸润

2026-04-100
OAAI
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
2025-11-120
PRE
The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis

高分子风险突变数量的增加可预测原发性及继发性骨髓纤维化患者造血干细胞移植后的预后。

2025-10-210
OA
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

培门冬酶(Pegaspargase)在55岁及以上急性淋巴细胞白血病患者的给药方案与耐受性研究:LAL1913方案的子分析,Campus ALL研究组。

2025-08-270
OAAI
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial

成人皮下注射blinatumomab治疗复发或难治性B细胞急性淋巴细胞白血病:一项多中心、单臂、Ⅰ/Ⅱ期试验的事后安全性和有效性分析

2025-06-150
PRE
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation

供者来源的经 Sleeping Beauty 转座子工程改造的 CARCIK-CD19 细胞在急性淋巴细胞白血病异基因移植后复发。

2025-04-030
OA
Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

与急性髓性白血病相比,急性淋巴细胞白血病中侵袭性肺曲霉病的不同流行病学: 一项关于Rete Ematologica Lombarda的前瞻性多中心观察研究的结果

2025-02-120
PRE
CD19 CAR T Cells Drive a Remodeling of the Immune Microenvironment Associated with T-Cell Dysfunction in Acute Lymphoblastic Leukemia

CD19 CAR T细胞驱动与急性淋巴细胞白血病中T细胞功能障碍相关的免疫微环境重塑。

BLOOD
IF23.1
2024-11-050
PRE
Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph plus Acute Lymphoblastic Leukemia Patients

Dasatinib联合Blinatumomab与Ponatinib联合Blinatumomab在 newly diagnosed Ph plus acute lymphoblastic leukemia 患者中的免疫调节效应比较

BLOOD
IF23.1
2024-11-050
PRE
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in the Setting of the Gimema ALL2820 Trial

可测量残留病灶监测在Gimema ALL2820试验中针对费城染色体阳性急性淋巴细胞白血病(Ph plus ALL)的应用

BLOOD
IF23.1
2024-11-050
PRE
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study
2024-08-152
OAAI
Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience

纳洛普利单抗在移植相关性血栓性微血管病患儿和成人患者中的安全性与有效性:一项真实世界研究经验

2024-05-210
OAAI